Molecular Medicine

, Volume 17, Issue 1–2, pp 41–47 | Cite as

Identification of Phospholipid Scramblase 1 as a Biomarker and Determination of Its Prognostic Value for Colorectal Cancer

  • Yung-Bin Kuo
  • Chung-Chuan Chan
  • C. Allen Chang
  • Chung-Wei Fan
  • Ray-Ping Hung
  • Ya-Shu Hung
  • Kuei-Tien Chen
  • Jau-Song Yu
  • Yu-Sun Chang
  • Err-Cheng Chan
Research Article


The purpose of this study was to examine the expression of phospholipid scramblase 1 (PLSCR1) in tumor tissues and plasma specimens of patients with colorectal cancer (CRC), as well as analyze its association with clinical parameters. The expression levels of PLSCR1 protein in 104 matched CRC and adjacent normal tissue sections and 50 pairs of CRC tissue blocks were determined by use of immunohistochemical and Western blot analyses, respectively. To evaluate the diagnostic potential of PLSCR1, the plasma levels of PLSCR1 were investigated in 111 additional subjects (59 CRC patients and 52 healthy controls) by Western blot. PLSCR1 was overexpressed in malignant adenocarcinoma tissues compared with normal colorectal mucosa (P < 0.001). In addition, the plasma level of PLSCR1 was not only significantly elevated in CRC patients compared with healthy individuals (P < 0.001), but it was also substantially increased in early stage CRC (P < 0.001). Importantly, the overall sensitivity and specificity of PLSCR1 for CRC detection were 80% and 59.6%, respectively. The area under the ROC curve of PLSCR1 for CRC diagnosis is 0.75, which increases to 0.8 if combined with the measurement of carcinoembryonic antigen. Univariate analysis with the Cox regression model revealed that elevated PLSCR1 expression indicated a poor prognosis for CRC. This study showed that PLSCR1 protein levels were significantly elevated in both the cancer tissue and plasma of CRC patients. Moreover, the plasma levels of PLSCR1 were significantly elevated in patients with early stage CRC compared with healthy individuals, suggesting that PLSCR1 might be used as a noninvasive serological diagnostic and prognostic biomarker for CRC.



This work was supported by grants (CMRPD180271 and CMRPG371431) from Chang Gung University and Chang Gung Memorial Hospital, Taiwan. CA Chang thanks the National Science Council of the Republic of China (Taiwan) for financial support (grant number NSC-98-2113-M-010-001-MY3).

Supplementary material

10020_2011_1701041_MOESM1_ESM.tif (94 kb)
Supplementary material, approximately 95 KB.
10020_2011_1701041_MOESM2_ESM.doc (74 kb)
Supplementary material, approximately 75 KB.


  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P. (2005) Global cancer statistics, 2002. CA Cancer J. Clin. 55:74–108.CrossRefGoogle Scholar
  2. 2.
    Kinzler KW, Vogelstein B. (1996) Lessons from hereditary colorectal cancer. Cell. 87:159–70.CrossRefGoogle Scholar
  3. 3.
    Hardcastle JD, et al. (1996) Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 348:1472–7.CrossRefGoogle Scholar
  4. 4.
    Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. (1996) Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 348:1467–71.CrossRefGoogle Scholar
  5. 5.
    Walsh JM, Terdiman JP. (2003) Colorectal cancer screening: scientific review. JAMA. 289:1288–96.CrossRefGoogle Scholar
  6. 6.
    Winawer S, et al. (2003) Colorectal cancer screening and surveillance: clinical guidelines and rationale—update based on new evidence. Gastroenterology. 124:544–60.CrossRefGoogle Scholar
  7. 7.
    Inger DB. (1999) Colorectal cancer screening. Prim. Care. 26:179–87.CrossRefGoogle Scholar
  8. 8.
    Ahlquist DA. (1997) Fecal occult blood testing for colorectal cancer: can we afford to do this? Gastroenterol. Clin. North Am. 26:41–55.CrossRefGoogle Scholar
  9. 9.
    Collins JF, Lieberman DA, Durbin TE, Weiss DG. (2005) Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann. Intern. Med. 142:81–5.CrossRefGoogle Scholar
  10. 10.
    Duffy MJ, et al. (2007) Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur. J. Cancer. 43:1348–60.CrossRefGoogle Scholar
  11. 11.
    Levy M, Visokai V, Lipska L, Topolcan O. (2008) Tumor markers in staging and prognosis of colorectal carcinoma. Neoplasma. 55:138–42.PubMedGoogle Scholar
  12. 12.
    Thomson DM, Krupey J, Freedman SO, Gold P. (1969) The radioimmunoassay of circulating carcinoembryonic antigen of the human digestive system. Proc. Natl. Acad. Sci. U. S. A. 64:161–7.CrossRefGoogle Scholar
  13. 13.
    Hundt S, Haug U, Brenner H. (2007) Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol. Biomarkers Prev. 16:1935–53.CrossRefGoogle Scholar
  14. 14.
    Basse F, Stout JG, Sims PJ, Wiedmer T. (1996) Isolation of an erythrocyte membrane protein that mediates Ca2+-dependent transbilayer movement of phospholipid. J. Biol. Chem. 271:17205–10.CrossRefGoogle Scholar
  15. 15.
    Zhao J, Zhou Q, Wiedmer T, Sims PJ. (1998) Level of expression of phospholipid scramblase regulates induced movement of phosphatidylserine to the cell surface. J. Biol. Chem. 273:6603–6.CrossRefGoogle Scholar
  16. 16.
    Zhou Q, et al. (1997) Molecular cloning of human plasma membrane phospholipid scramblase: a protein mediating transbilayer movement of plasma membrane phospholipids. J. Biol. Chem. 272:18240–4.CrossRefGoogle Scholar
  17. 17.
    Frasch SC, et al. (2000) Regulation of phospholipid scramblase activity during apoptosis and cell activation by protein kinase Cdelta. J. Biol. Chem. 275:23065–73.CrossRefGoogle Scholar
  18. 18.
    Sims PJ, Wiedmer T. (2001) Unraveling the mysteries of phospholipid scrambling. Thromb. Haemost. 86:266–75.CrossRefGoogle Scholar
  19. 19.
    Kasukabe T, Okabe-Kado J, Honma Y. (1997) TRA1, a novel mRNA highly expressed in leukemogenic mouse monocytic sublines but not in nonleukemogenic sublines. Blood. 89:2975–85.PubMedGoogle Scholar
  20. 20.
    Silverman RH, et al. (2002) Suppression of ovarian carcinoma cell growth in vivo by the interferon-inducible plasma membrane protein, phospholipid scramblase 1. Cancer Res. 62:397–402.PubMedGoogle Scholar
  21. 21.
    Chen JS, et al. (2010) Comparison of membrane fraction proteomic profiles of normal and cancerous human colorectal tissues with gel-assisted digestion and iTRAQ labeling mass spectrometry. FEBS J. 277:3028–38CrossRefGoogle Scholar
  22. 22.
    Cattoretti G, et al. (1993) Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections. J. Pathol. 171:83–98.CrossRefGoogle Scholar
  23. 23.
    Cao WF, et al. (2007) Prognostic significance of stomatin-like protein 2 overexpression in laryngeal squamous cell carcinoma: clinical, histologic, and immunohistochemistry analyses with tissue microarray. Hum. Pathol. 38:747–52.CrossRefGoogle Scholar
  24. 24.
    Feng Han Q, et al. (2006) Expression of sFRP-4 and beta-catenin in human colorectal carcinoma. Cancer Lett. 231:129–37.CrossRefGoogle Scholar
  25. 25.
    Zwaal RF, Comfurius P, Bevers EM. (2005) Surface exposure of phosphatidylserine in pathological cells. Cell Mol. Life Sci. 62:971–88.CrossRefGoogle Scholar
  26. 26.
    Huang Y, et al. (2006) Antileukemic roles of human phospholipid scramblase 1 gene, evidence from inducible PLSCR1-expressing leukemic cells. Oncogene. 25:6618–27.CrossRefGoogle Scholar
  27. 27.
    Pastorelli C, et al. (2001) IgE receptor type I-dependent tyrosine phosphorylation of phospholipid scramblase. J. Biol. Chem. 276:20407–12.CrossRefGoogle Scholar
  28. 28.
    Sun J, et al. (2001) c-Abl tyrosine kinase binds and phosphorylates phospholipid scramblase 1. J. Biol. Chem. 276:28984–90.CrossRefGoogle Scholar
  29. 29.
    Dong B, et al. (2004) Phospholipid scramblase 1 potentiates the antiviral activity of interferon. J. Virol. 78:8983–93.CrossRefGoogle Scholar
  30. 30.
    Nakamaki T, et al. (2002) Role of MmTRA1b/phospholipid scramblase1 gene expression in the induction of differentiation of human myeloid leukemia cells into granulocytes. Exp. Hematol. 30:421–9.CrossRefGoogle Scholar
  31. 31.
    Kim H, et al. (2006) Suppression of human selenium-binding protein 1 is a late event in colorectal carcinogenesis and is associated with poor survival. Proteomics. 6:3466–76.CrossRefGoogle Scholar
  32. 32.
    Alfonso P, et al. (2005) Proteomic expression analysis of colorectal cancer by two-dimensional differential gel electrophoresis. Proteomics. 5:2602–11.CrossRefGoogle Scholar
  33. 33.
    Friedman DB, et al. (2004) Proteome analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics. 4:793–811.CrossRefGoogle Scholar
  34. 34.
    Roessler M, et al. (2005) Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer. Clin. Cancer Res. 11:6550–7.CrossRefGoogle Scholar
  35. 35.
    Stulik J, et al. (2001) Proteome study of colorectal carcinogenesis. Electrophoresis. 22:3019–25.CrossRefGoogle Scholar
  36. 36.
    Roessler M, et al. (2006) Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis. Mol. Cell. Proteomics. 5:2092–101.CrossRefGoogle Scholar
  37. 37.
    Huber K, et al. (1993) Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: comparison with circulating tumor-associated antigens CA 19–9 and carcinoembryonic antigen. Cancer Res. 53:1788–93.PubMedGoogle Scholar
  38. 38.
    Bast RC Jr, et al. (2001) 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. 19:1865–78.CrossRefGoogle Scholar
  39. 39.
    Kim HJ, Yu MH, Kim H, Byun J, Lee C. (2008) Noninvasive molecular biomarkers for the detection of colorectal cancer. BMB Rep. 41:685–92.CrossRefGoogle Scholar
  40. 40.
    Huang Y, Zhao Q, Chen GQ. (2006) Phospholipid scramblase 1. Acta Physiol. Sin. 58:501–10.Google Scholar
  41. 41.
    Sahu SK, Gummadi SN, Manoj N, Aradhyam GK. (2007) Phospholipid scramblases: an overview. Arch. Biochem. Biophys. 462:103–14.CrossRefGoogle Scholar
  42. 42.
    Lu B. et al. (2007) Expression of the phospholipid scramblase (PLSCR) gene family during the acute phase response. Biochim. Biophys. Acta. 1771:1177–85.CrossRefGoogle Scholar
  43. 43.
    Mor G, et al. (2005) Serum protein markers for early detection of ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 102:7677–82.CrossRefGoogle Scholar
  44. 44.
    Schneider J, Bitterlich N, Schulze G. (2005) Improved sensitivity in the diagnosis of gastro-intestinal tumors by fuzzy logic-based tumor marker profiles including the tumor M2-PK. Anticancer Res. 25:1507–15.PubMedGoogle Scholar
  45. 45.
    Yokoyama A, et al. (2004) MmTRA1b/phospholipid scramblase 1 gene expression is a new prognostic factor for acute myelogenous leukemia. Leuk. Res. 28:149–57.CrossRefGoogle Scholar

Copyright information

© The Feinstein Institute for Medical Research 2011

Authors and Affiliations

  • Yung-Bin Kuo
    • 1
  • Chung-Chuan Chan
    • 2
  • C. Allen Chang
    • 1
    • 3
  • Chung-Wei Fan
    • 4
  • Ray-Ping Hung
    • 5
  • Ya-Shu Hung
    • 5
  • Kuei-Tien Chen
    • 5
  • Jau-Song Yu
    • 6
  • Yu-Sun Chang
    • 7
  • Err-Cheng Chan
    • 5
  1. 1.College of Biological Science and TechnologyNational Chiao Tung UniversityHsinchuTaiwan
  2. 2.Department of GastroenterologyHsinchu Cathay General HospitalHsinchuTaiwan
  3. 3.Department of Biomedical Imaging and Radiological SciencesNational Yang-Ming UniversityTaipeiTaiwan
  4. 4.Department of Colorectal SurgeryChang Gung Memorial HospitalKeelungTaiwan
  5. 5.Department of Medical Biotechnology and Laboratory ScienceChang Gung UniversityTaoyuanTaiwan
  6. 6.Cell and Molecular BiologyChang Gung UniversityTaoyuanTaiwan
  7. 7.Molecular Medicine Research CenterChang Gung UniversityTaoyuanTaiwan

Personalised recommendations